TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03281161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces Program
Description: A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
Study: NCT02815579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shamba Maisha Intervention
Description: A) A loan (\~$175) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
Study: NCT03789097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: an immune cell activating factor. vials containing 1 ml of 2 mg/mL
Study: NCT02529254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video coaching session
Description: A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
Study: NCT02784457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Study: NCT01185470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Morphine Sulfate delivering programmable pump
Description: Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
Study: NCT04522557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFNα-2a
Description: After mastectomy, it is used in the cavity of breast before conducting implantation.
Study: NCT04303195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT04014010

Intervention type: OTHER
Intervention: Blood pressure
Description: Systolic Blood Pressure (SBP)~1. Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative SBP~3. Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~4. Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~1. Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative MAP~3. Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~4. Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg

Intervention type: OTHER
Intervention: Heart rate
Description: 1. Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~2. Relative change (%) from preoperative heart rate (positive and negative)~3. Maximum pulse variation (maximum heart rate minus minimum heart rate)~4. Longest single episode (minutes) a) below 60, and b) above 100BPM~5. Cumulative duration (minutes) a) below 60, and b) above 100BPM

Intervention type: OTHER
Intervention: Use of hemodynamic medications (i.e. special medications for blood pressure)
Description: 1. Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~2. Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~3. Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~4. Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~5. Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)

Intervention type: OTHER
Intervention: Oxygen saturation by pulse oximetry (SpO2)
Description: 1. Longest single episode (minutes) below a) 88, and b) 90%~2. Cumulative duration (minutes) below a) 88, and b) 90%

Intervention type: OTHER
Intervention: End-tidal Carbon dioxide (EtCO2)
Description: 1. Longest single episode (minutes) a) below 30, and b) above 45mmHg~2. Cumulative duration (minutes) a) below 30, and b) above 45mmHg
Study: NCT03438201

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
Study: NCT02843126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: For each procedure, 10 billion cells will be infused for 4 times
Study: NCT01275443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg TMC278LA
Description: 300mg TMC278LA intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg TMC278LA
Description: 150mg TMC278LA intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200mg TMC278LA
Description: 1200mg TMC278LA intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg TMC278LA
Description: 600mg TMC278LA intramuscular injection
Study: NCT01016145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Description: Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotics
Description: Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
Study: NCT02057263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants will receive 4 doses of alendronate during the course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 4 doses of placebo during the course of the study.
Study: NCT01481558

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS 2 mA, dorsolateral pre-frontal cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS 2 mA, dorsolateral pre-frontal cortex
Study: NCT00965237

Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B multifocal contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
Study: NCT02460575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 17938
Description: probiotic
Study: NCT00965237

Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B multifocal contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B single vision contact lens
Description: Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B single vision contact lens
Description: Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use

Intervention type: OTHER
Group type: OTHER
Intervention: Over-reader spectacles
Description: Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis

Intervention type: OTHER
Group type: OTHER
Intervention: Over-reader spectacles
Description: Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
Study: NCT00571662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 4 mg/m\^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-body irradiation (TBI)
Description: TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Description: CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day subcutaneously for at least 4 consecutive days.
Study: NCT02460575

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
Study: NCT02162004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Correction
Study: NCT03561298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111 and Drug Cocktail
Description: BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
Study: NCT00970645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mediastinoscopy/thoracoscopy
Description: Mediastinoscopy used to detect/stage lung cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS/EUS
Description: Minimal invasive technique to stage/detect lung cancer.
Study: NCT04543175

Intervention type: OTHER
Intervention: Taste disorder´s test
Description: Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
Study: NCT03356600

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Apatinib plus radiotherapy
Description: Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy
Study: NCT01533116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Study: NCT04043143

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arm 1 Prescription As Usual
Description: At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2 Prescription Tool Intervention
Description: The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
Study: NCT03480477

Intervention type: OTHER
Intervention: ACE questionnaire
Description: No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire

Intervention type: OTHER
Intervention: ACE questionnaire
Description: No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire

Intervention type: OTHER
Intervention: ACE questionnaire
Description: No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire
Study: NCT03079297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Leucine
Description: L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
Study: NCT00703066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ 2 vaccine (GLURP + MSP 3)
Description: three doses of 30µg of GMZ 2 vaccine,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ 2 vaccine (GLURP + MSP 3)
Description: 100 µg of GMZ 2 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: 3 doses of Rabies vaccine
Study: NCT01330849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHD Toolkit
Description: For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Waiting List Control group
Description: Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
Study: NCT01480063

Intervention type: DRUG
Intervention: Fampridine
Description: Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
Study: NCT00618176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)
Description: Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W\>60Kg)125mg bid (W\<60Kg) Nevirapine (NVP) 200mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)
Description: Stavudine (d4T) 30mg bid (W\>60Kg)20mg bid (W\<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
Description: Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
Study: NCT02209493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food supplementation: nopales
Description: Consumption of 2 cups/day of test food: nopales

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Food supplementation: cucumber
Description: Consumption of 2 cups/day of test food: cucumber
Study: NCT02585323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education session, Fitbit/FitViz, PT counselling
Description: Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 3 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
Study: NCT03260478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red Blood Cells Transfusion
Description: Transfusion of packed red blood cells unit(s).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red Blood Cells Transfusion
Description: Transfusion of packed red blood cells unit(s).
Study: NCT02179177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Drug is taken by mouth twice a day for 6 months
Study: NCT01533116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide
Study: NCT02179177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01022541

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above.
Study: NCT01533116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide
Study: NCT01022541

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above.
Study: NCT03110133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Spectrum Microbiota
Description: Orally administered donor derived microbiota

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for CP101
Study: NCT01022541

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver metastasectomy
Description: Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
Study: NCT04288518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT or SPECT-CT with 99mTc-1-thio-D-glucose
Description: One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study: NCT03328247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASICA digital app
Description: Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
Study: NCT02958371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fruit-flavored drink ingestion
Study: NCT04288518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT or SPECT-CT with 99mTc-1-thio-D-glucose
Description: One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT or SPECT-CT with 99mTc-1-thio-D-glucose
Description: One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study: NCT04400487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: 500 mg Tablet, Oral, With or Without Food